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Transcatheter aortic valve in mitral annular 
calcifi cation (TAV-in-MAC): A new treatment 
option for mitral valve replacement in 
patients with severe annular calcifi cation
TREATMENT 
OPTION 
FOR MAC
to function well, but she had severe mitral valve stenosis with a 
valve area of 0.6cm2 and a mean gradient of 14mmHg. The 
gradients over the aortic prosthesis were 17/8mmHg. She had, 
at least, moderate mitral regurgitation and severe pulmonary 
hypertension (pulmonary arterial pressures of 60mmHg). A CT 
scan confirmed severe MAC (Figure 1), which excluded con-
ventional surgery. She presented twice in a 7-week period 
with pulmonary oedema and a decision was taken to offer her 
a procedure.
ABSTRACT
Severe mitral annular calcifi cation is not an uncommon 
occurrence in the elderly and up to now, this has often 
precluded surgical replacement of the mitral valve. Initial 
attempts at percutaneous placement of transcatheter 
aortic valves in the calcifi ed mitral annulus, has not been 
very successful due to obstruction of the left ventricular 
outfl ow tract. We describe a surgical approach where 
the anterior mitral valve leafl et was resected and a 
balloon expandable transcatheter aortic valve then 
deployed withing the calcifi ed annulus. The benefi ts of 
this technique over a fully percutaneous approach is 
discussed.   SAHeart 2019;16:136-139
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INTRODUCTION
Since the first transcatheter aortic valve implant (TAVI) in 
2002,(1) the field has enjoyed exponential growth. Interventions 
for the mitral valve, however, have lagged due to the more 
complex structure of the mitral valve. Candidates for mitral 
valve surgery tend to be younger and therefore surgical 
candidates. A significant group of elderly patients, however, are 
denied any surgical intervention because of excessive mitral 
annular calcification (MAC). Our group performed the first 
percutaneous aortic and mitral valve replacement(2) but this led 
to severe left ventricular outflow tract (LVOT) obstruction due 
to displacement of the anterior mitral valve leaflet (AMVL) into 
the LVOT. This complication turned out to be the Achilles’ heel 
of the procedure. Surgical excision of the anterior mitral valve 
leaflet may be the solution to this problem and we describe 
such a case.
PATIENT HISTORY
A 79-year-old female patient was referred with dyspnoea. She 
had been living independently on a farm despite a previous 
aortic valve replacement (mechanical prosthesis for degenera-
tive aortic stenosis 14 years prior) and chronic atrial fibrillation 
with good rate control. The aortic valve prosthesis was found 
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FIGURE 1: CT scan image showing the severely calcifi ed 
mitral annulus in a long axis view.
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THE PROCEDURE
The procedure was performed in a hybrid theatre under 
general anaesthesia on a beating heart. The patient was 
positioned on her back with her right arm in an abducted 
position and a sandbag under her scapula. The right femoral 
vessels were cannulated with a Bio-Medicus (Medtronic, MN) 
21FG arterial cannula and a 23FG venous cannula. A right 
mini-thoracotomy in the fourth intercostal space (ICS) was 
performed and an endoscope inserted in the second ICS, lateral 
clavicular line for an optimal viewing angle. Cardiopulmonary 
bypass (CPB) was initiated: an aortic root vent and right 
superior pulmonary vein vent was inserted. Due to the fact that 
she has a porcelain aorta, the aorta was not cross-clamped. 
Because the procedure was done on a beating heart, concern 
existed that air may pass through the mechanical aortic valve. 
To address this, the patient was tilted head down (Trendelen-
burg position), and the mean arterial pressure kept above 
75mmHg and placed an ascending aorta vent as well as a left 
ventricular vent. Waterstone’s groove was dissected, the left 
atrium was opened, and a left atrial retractor was placed 
through the thoracotomy (Figure 2 demonstrates the anatomy 
as seen at this stage).
The antero-medial mitral commissure was plicated with a single 
pledgeted suture to create a more circular annulus and poten-
tially less chance of paravalvular leakage. The postero-medial 
commissure was too calcified to suture. The anterior mitral 
valve leaflet and chords were then resected (see Figure 3 and 
online Video 1).The orifice was sized with a 25mm balloon and 
a 26mm Edwards SAPIEN XT valve (Edwards Lifesciences, 
Irvine, CA) was implanted. The valve was mounted in an inverse 
orientation on the delivery system and rotated to an orienta-
FIGURE 2: A view of the mitral valve from the atrial side 
to show orientation: the antero-lateral commissure (blue 
arrow) was plicated and the postero-medial commissure 
(green arrow) was too calcifi ed to suture. The position of 
the aortic valve is shown as a superimposed blue disc.
FIGURE 4: The Edwards SAPIEN XT valve after the fi rst 
deployment. Note how much of it is visible on the atrial 
side. A paravalvular jet was seen at 10 o’clock and the 
valve was removed.
FIGURE 5: The valve after a second deployment sitting 
signifi cantly less atrial and no leaks were seen. The 
pledgeted sutures seen were then used to put anchor 
sutures through the struts of the stent.
FIGURE 3: After plication of the antero-lateral com-
missure, the A2 portion of the anterior leafl et was 
resected together with its chords – the blue arrow 
indicates the A2 segment as it is pulled out.
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tion that ensured none of the SAPIEN XT valve’s commissures 
were over the LVOT. It was deployed under direct vision and 
without rapid ventricular pacing (see online Video 2). This initial 
position was too atrial (see Figure 4 and online Video 3) and 
resulted in a paravalvular leak. The fact that the heart was 
beating enabled us to detect this leak immediately. The device 
was removed and recrimped. A second deployment resulted in 
a better position (see Figure 5 and online Video 3). The valve 
stent was fixed with 2 pledgeted sutures.
The patient was weaned from CPB and intra-operative trans-
oesophageal echo showed a mean LVOT gradient of 8.3mmHg, 
minimal paravalvular leak and good valve function (see online 
Video 4). The patient was extubated the next morning, made 
an uncomplicated recovery and was discharged on day 6. 
A follow up echo did not show any paravalvular leaks and a 
mean gradient of 3mmHg over the mitral valve. She remains in 
NYHA functional class 1.
DISCUSSION
Conventional mitral valve replacement surgery for patients with 
severe MAC is often not possible or carries high risk due to the 
surgeon’s inability to place sutures in the annulus or the extent 
of debridement required to place the valve.(3) We describe the 
first case of a transcatheter aortic valve prosthesis implanted 
into a calcified native mitral annulus (TAV-in-MAC) published 
in South Africa. TAV-in-MAC was first described in 2013(4) 
but this approach has met slow acceptance for a number of 
reasons. In the largest series reported (n=64), more than 30% 
of screened patients were excluded from the procedure 
because their anatomy was deemed unsuitable. Access was 
transapical (45%) and transseptal (40%) in most cases and the 
authors did not mention how often the AMVL was resected in 
the transatrial cases. Procedural success was achieved in 72% 
with high rates of clinically significant LVOT obstruction (9%) 
and the need for a second valve (17%). Signif icant LVOT 
obstruction was fatal in all but 1 case and the authors unfortu-
nately did not report on LVOT gradients in the majority of 
other cases. It therefore remains unknown to what extent this 
complication influences the outcome of patients who survive 
the procedure. Thirty-day mortality was 29.7% and technical 
success was worst with transseptal approach (65%), followed 
by transapical (71%) and transatrial (89%).(5) These sobering 
results may be due to a number of factors but inability to 
predict LVOT obstruction may be a significant one and our 
approach was to assume the worst and address this risk prior 
to implantation of the valve. 
Pre-operative imaging is crucial. Apart from the correct diag-
nosis of severe mitral stenosis (which may be very challenging), 
it is important to confirm the degree of MAC on CT-scanning. 
A CT scan can also help to determine the risk of LVOT 
obstruction. There is no validated method of predicting this, but 
techniques utilised include measuring the angle between the 
planes of the aorta and mitral valves (if it is <120 degrees, 
LVOT obstruction is more likely) and special software that 
enables superimposing the intended transcatheter valve on the 
annulus and calculating the LVOT area.(6)
A percutaneous alternative would be preferable, provided the 
results are similar. In the series described above, the success 
rate and mortality was higher in the percutaneous arms of the 
studies. The authors, however, did not report on the occurrence 
of the main complications (LVOT obstruction and valve 
embolisation) stratified according to access site. Our approach 
is that both of these can be managed better with a transatrial 
approach. During percutaneous implantation, most operators 
flared the ventricular side of the prosthesis to enable better 
anchoring.(5) Whilst this may improve anchoring, it is not known 
whether the altered geometry of the stent will have a negative 
influence on the valve function and longevity. The first attempt 
at addressing LVOT obstruction percutaneously was alcohol 
septal ablation (either electively prior to the valve replacement 
or as a bail out) but this has been shown to be associated with 
mortality.(5) More recently, a technique of percutaneously 
bisecting the anterior mitral valve leaflet – so called LAMPOON 
technique – was described.(7) This, however, requires specialised 
equipment, was tested mainly in patients with either a mitral 
annuloplasty ring or a surgical mitral valve ring and does not 
allow for resection of the anterior chords. Patients who are not 
good surgical candidates due to comorbidities rather than 
technical limitations, may benefit from these procedures. 
We are of the opinion that in patients who are surgical 
candidates the transatrial approach holds certain important 
advantages over current percutaneous approaches:
 ■ The same degree of debulking of the AMVL and chords 
cannot be achieved percutaneously.
 ■ LVOT obstruction cannot be predicted reliably yet and bail-
out alternatives, if it occurs, are limited.
 ■ Plication of 1 or both mitral annuli probably reduces para-
valvular leaks and enables insertion of a smaller valve with 
less chance of LVOT obstruction.
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 ■ Valve embolisation is common with percutaneous tech-
niques(5, 8) and suture anchoring of the valve should reduce 
this.
 ■ Rotating the TAV prosthesis to enable optimal orientation 
of cusps.
 ■ Operating on a beating heart enables evaluation and cor-
rection of paravalvular leaks intra-operatively.
 ■ Retrieving a valve is possible, should it be required.
Degenerative mitral stenosis with severe MAC is a common 
problem in older patients and,  until recently, there have been 
very few treatment options for these patients. We believe that 
TAV-in-MAC offers a new treatment modality that may benefit 
a significant proportion of these patients. 
Conflict of interest: none declared. 
REFERENCES
1. Cribier A, Eltchaninoff H, Tron C. First human transcatheter implantation of 
an aortic valve prosthesis in a case of severe calcific aortic stenosis. Ann 
Cardiol Angeiol (Paris) 2003;52(0003-3928;3):173-75.
2. Weich H, Janson J, Pecoraro A, et al. First case of transcatheter native mitral 
and aortic valve replacement. EuroIntervention 2016;12(9). DOI: 10.4244/
EIJV12I9A195.
3. Sud K, Agarwal S. Degenerative mitral stenosis unmet need for percuta-
neous interventions. Circulation 2016;133:1594-604. DOI: 10.1161/
CIRCULATIONAHA.115.020185.
4. Hasan R, Mahadevan VS, Schneider H, Clarke B. First in human transapical 
implantation of an inverted transcatheter aortic valve prosthesis to treat 
native mitral valve stenosis. Circulation 2013;128(6):e74-76. DOI: 10.1161/
CIRCULATIONAHA.113.001466.
5. Guerrero M, Dvir D, Himbert D, et al. Transcatheter mitral valve replace-
ment in native mitral valve disease with severe mitral annular calcification: 
Results from the first multicentre global registry 2016.
6. Eleid MF, Foley TA, Said SM, Pislaru SV, Rihal CS. Severe mitral annular 
calcification: Multimodality imaging for therapeutic strategies and interven-
tions. JACC Cardiovasc Imaging 2016;9(11):1318-37. DOI: 10.1016/J.JCMG.
2016.09.001.
7. Babaliaros VC, Greenbaum AB, Khan JM, et al. Intentional percutaneous 
laceration of the anterior mitral leaflet to prevent outflow obstruction during 
transcatheter mitral valve replacement. JACC Cardiovasc Interv 2017;
10(8):798-809. DOI: 10.1016/j.jcin.2017.01.035.
8. Lazkani M, Verma DR, Gellert G, Morris M, Fang K, Pershad A. Limitations 
of transcatheter mitral valve replacement in native mitral valve disease with 
severe mitral annular calcification. JACC Cardiovasc Interv 2016;9(23):
2460-61. DOI: 10.1016/j.jcin.2016.09.042.
